Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Apr 02, 2024

Read More

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Apr 01, 2024

Read More

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Mar 27, 2024

Read More

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Mar 13, 2024

Read More

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Mar 06, 2024

Read More

Zai Lab Announces Participation in March Investor Conference

Mar 06, 2024

Read More

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Feb 27, 2024

Read More

Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

Jan 25, 2024

Read More